{"id":"weekly-tc-chemotherapy","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"50-80%","effect":"Nausea and vomiting"},{"rate":"30-60%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This treatment modality leverages the cytotoxic effects of chemotherapy agents to induce cell death in cancerous tissues. The weekly schedule aims to maintain a consistent and sustained exposure to the drugs, potentially enhancing their efficacy.","oneSentence":"Weekly TC chemotherapy involves administering a combination of chemotherapy drugs on a weekly schedule to target rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:01.219Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT07102940","phase":"PHASE2","title":"Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"George Washington University","startDate":"2026-05-01","conditions":"Breast Cancer, HER 2 Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer","enrollment":50},{"nctId":"NCT07306663","phase":"PHASE3","title":"Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2021-06-01","conditions":"Esophageal Cancer","enrollment":242},{"nctId":"NCT05256745","phase":"PHASE1, PHASE2","title":"RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2023-06-06","conditions":"Cancer Related Cognitive Decline, Non-metastatic Breast Cancer","enrollment":48},{"nctId":"NCT04105270","phase":"PHASE2","title":"RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2022-11-30","conditions":"Adenocarcinoma of Lung, Lung Cancer","enrollment":82},{"nctId":"NCT06509568","phase":"PHASE2","title":"Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-08-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":92},{"nctId":"NCT03705429","phase":"PHASE3","title":"A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2019-05-01","conditions":"Breast Neoplasms","enrollment":51},{"nctId":"NCT01547741","phase":"PHASE3","title":"Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer","status":"UNKNOWN","sponsor":"NSABP Foundation Inc","startDate":"2012-04","conditions":"Breast Cancer","enrollment":1871},{"nctId":"NCT05131893","phase":"","title":"Neoadjuvant Treatment of Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Oncology, Hungary","startDate":"2022-03","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT03728829","phase":"","title":"Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer","status":"UNKNOWN","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2021-07","conditions":"Observational, Prospective","enrollment":100},{"nctId":"NCT00542191","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer","status":"TERMINATED","sponsor":"Leo W. Jenkins Cancer Center","startDate":"2007-07","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT04127019","phase":"PHASE3","title":"Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2010-06-01","conditions":"Primary Breast Cancer","enrollment":2079},{"nctId":"NCT01501487","phase":"PHASE4","title":"MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I","status":"COMPLETED","sponsor":"Agendia","startDate":"2011-10","conditions":"Breast Cancer","enrollment":226},{"nctId":"NCT00256243","phase":"PHASE2","title":"Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer","status":"COMPLETED","sponsor":"Rita Sanghvi, Mehta","startDate":"2004-04","conditions":"Breast Cancer","enrollment":48},{"nctId":"NCT03366883","phase":"PHASE3","title":"Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2018-02-01","conditions":"Esophageal Cancer Stage IIB, Esophageal Cancer Stage III","enrollment":420},{"nctId":"NCT01917578","phase":"PHASE3","title":"Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2008-08","conditions":"Breast Cancer","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Weekly TC Chemotherapy","genericName":"Weekly TC Chemotherapy","companyName":"Jiangsu Cancer Institute & Hospital","companyId":"jiangsu-cancer-institute-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Weekly TC chemotherapy is a treatment for hormone receptor positive/HER2-negative breast cancer, typically administered in a neoadjuvant setting. It involves the intravenous administration of docetaxel and cyclophosphamide on a weekly schedule.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}